Twist Bioscience Past Earnings Performance
Past criteria checks 0/6
Twist Bioscience's earnings have been declining at an average annual rate of -17.6%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 35.8% per year.
Key information
-17.6%
Earnings growth rate
14.3%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 35.8% |
Return on equity | -34.9% |
Net Margin | -78.4% |
Next Earnings Update | 02 May 2024 |
Recent past performance updates
Recent updates
Twist Bioscience Corporation (NASDAQ:TWST) Surges 26% Yet Its Low P/S Is No Reason For Excitement
Feb 27Twist Bioscience: Strong Performance In A Soft Market
Feb 07Here's Why Shareholders May Want To Be Cautious With Increasing Twist Bioscience Corporation's (NASDAQ:TWST) CEO Pay Packet
Jan 31We're Not Very Worried About Twist Bioscience's (NASDAQ:TWST) Cash Burn Rate
Jan 22Twist Bioscience Corporation's (NASDAQ:TWST) Price Is Right But Growth Is Lacking After Shares Rocket 44%
Dec 18Twist Bioscience (NASDAQ:TWST) Is In A Good Position To Deliver On Growth Plans
Oct 05We Think Twist Bioscience (NASDAQ:TWST) Can Afford To Drive Business Growth
Jul 07Twist Biosciences collaborates with Enzolytics on monoclonal antibodies for viruses
Sep 16Twist Bioscience: DNA Synthesis Leader Appealing 'Picks And Shovels' Play
Sep 02Twist Bioscience: DNA Synthesis Leader Is Just Getting Started
Aug 08Twist Bioscience/ Biotia sequencing assay granted FDA nod to detect COVID variants
Aug 02Twist Biosciences to work with DNAnexus on sequencing-based diagnostic tests
Jul 13Twist Bioscience, Ildong team up to discover antibodies for cancer therapies
Jun 30Twist Bioscience: A First Take
May 26Revenue & Expenses BreakdownBeta
How Twist Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 262 | -206 | 200 | 99 |
30 Sep 23 | 245 | -205 | 190 | 107 |
30 Jun 23 | 235 | -209 | 195 | 113 |
31 Mar 23 | 228 | -213 | 203 | 125 |
31 Dec 22 | 216 | -214 | 204 | 129 |
30 Sep 22 | 204 | -218 | 213 | 120 |
30 Jun 22 | 184 | -208 | 197 | 110 |
31 Mar 22 | 163 | -188 | 178 | 93 |
31 Dec 21 | 146 | -165 | 158 | 78 |
30 Sep 21 | 132 | -152 | 136 | 69 |
30 Jun 21 | 127 | -135 | 125 | 61 |
31 Mar 21 | 113 | -123 | 113 | 52 |
31 Dec 20 | 101 | -117 | 106 | 47 |
30 Sep 20 | 90 | -140 | 103 | 43 |
30 Jun 20 | 73 | -147 | 101 | 42 |
31 Mar 20 | 66 | -147 | 99 | 40 |
31 Dec 19 | 60 | -141 | 91 | 39 |
30 Sep 19 | 54 | -108 | 80 | 36 |
30 Jun 19 | 47 | -96 | 69 | 31 |
31 Mar 19 | 40 | -86 | 59 | 28 |
31 Dec 18 | 33 | -77 | 49 | 23 |
30 Sep 18 | 25 | -71 | 43 | 20 |
30 Jun 18 | 20 | -68 | 39 | 19 |
30 Sep 17 | 11 | -59 | 26 | 19 |
30 Sep 16 | 2 | -44 | 18 | 18 |
Quality Earnings: TWST is currently unprofitable.
Growing Profit Margin: TWST is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TWST is unprofitable, and losses have increased over the past 5 years at a rate of 17.6% per year.
Accelerating Growth: Unable to compare TWST's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TWST is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: TWST has a negative Return on Equity (-34.88%), as it is currently unprofitable.